Acumen Pharmaceuticals Stock Performance
| ABOS Stock | USD 2.31 0.06 2.53% |
The firm shows a Beta (market volatility) of 3.1, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Acumen Pharmaceuticals will likely underperform. At this point, Acumen Pharmaceuticals has a negative expected return of -0.25%. Please make sure to confirm Acumen Pharmaceuticals' treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Acumen Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Acumen Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in December 2024. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return (4.24) | Five Day Return (13.38) | Year To Date Return (46.35) | Ten Year Return (88.71) | All Time Return (88.71) |
1 | Acquisition by Barton Russell of 135000 shares of Acumen Pharmaceuticals at 5.19 subject to Rule 16b-3 | 09/06/2024 |
2 | Acumen Pharmaceuticals, Inc. Sees Large Drop in Short Interest - MarketBeat | 09/17/2024 |
3 | Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimers Disease | 09/26/2024 |
4 | Acumen Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference | 09/30/2024 |
5 | Renaissance Technologies LLC Invests 818,000 in Acumen Pharmaceuticals, Inc. - MarketBeat | 10/08/2024 |
6 | Acumen Pharmaceuticals to Deliver Late-Breaking Presentation at 17th Annual Clinical Trials on Alzheimers Disease Conference | 10/23/2024 |
7 | Insider Trading | 11/05/2024 |
8 | Acumen Pharmaceuticals Posts Earnings Results, Misses Estimates By 0.14 EPS | 11/14/2024 |
| Begin Period Cash Flow | 130.1 M | |
| Free Cash Flow | -43.1 M |
Acumen |
Acumen Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 291.00 in Acumen Pharmaceuticals on August 23, 2024 and sell it today you would lose (60.00) from holding Acumen Pharmaceuticals or give up 20.62% of portfolio value over 90 days. Acumen Pharmaceuticals is currently does not generate positive expected returns and assumes 4.7416% risk (volatility on return distribution) over the 90 days horizon. In different words, 42% of stocks are less volatile than Acumen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Acumen Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Acumen Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Acumen Pharmaceuticals, and traders can use it to determine the average amount a Acumen Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0522
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ABOS |
Estimated Market Risk
| 4.74 actual daily | 42 58% of assets are more volatile |
Expected Return
| -0.25 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Acumen Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Acumen Pharmaceuticals by adding Acumen Pharmaceuticals to a well-diversified portfolio.
Acumen Pharmaceuticals Fundamentals Growth
Acumen Stock prices reflect investors' perceptions of the future prospects and financial health of Acumen Pharmaceuticals, and Acumen Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Acumen Stock performance.
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (29.49 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Price To Book | 0.66 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (32.36 M) | ||||
| EBITDA | (51.61 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.49 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Earnings Per Share | (1.38) X | ||||
| Market Capitalization | 142.39 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
About Acumen Pharmaceuticals Performance
Assessing Acumen Pharmaceuticals' fundamental ratios provides investors with valuable insights into Acumen Pharmaceuticals' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Acumen Pharmaceuticals is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.17) | (0.18) | |
| Return On Capital Employed | (0.21) | (0.22) | |
| Return On Assets | (0.17) | (0.18) | |
| Return On Equity | (0.20) | (0.19) |
Things to note about Acumen Pharmaceuticals performance evaluation
Checking the ongoing alerts about Acumen Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Acumen Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Acumen Pharmaceuticals generated a negative expected return over the last 90 days | |
| Acumen Pharmaceuticals has high historical volatility and very poor performance | |
| Acumen Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (52.37 M) with loss before overhead, payroll, taxes, and interest of (32.36 M). | |
| Acumen Pharmaceuticals currently holds about 189.91 M in cash with (43.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.69, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Acumen Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Over 78.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Acumen Pharmaceuticals Posts Earnings Results, Misses Estimates By 0.14 EPS |
- Analyzing Acumen Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Acumen Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Acumen Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Acumen Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Acumen Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Acumen Pharmaceuticals' stock. These opinions can provide insight into Acumen Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.